How brain processes are rewired in Parkinson's disease

Published Date: 02 Mar 2023

Researchers from the University of Queensland have confirmed that genes associated with the risk of Parkinson's disease also contribute to the production of cellular debris in the brain.

Read Full News

Latest News

More Time in Target Blood Pressure Range Cuts Recurrent Stroke After Intracerebral Hemorrhage Marco Meglio

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia Marco Meglio

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

Liposomal Mitoxantrone Shows Early Safety Signal in Phase 2 NMOSD Trial Marco Meglio

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Todays Updates

Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status Marco Meglio

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

NeurologyLive® Friday 5 — October 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

Is Pregnancy Riskier for Living Kidney Donors? With Amit X. Garg, MD, PhD Amit X. Garg, MD, PhD

A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.

Counseling Kidney Donors on Future Pregnancy, With Amit Garg, MD, PhD Amit X. Garg, MD, PhD

Future pregnancy plans don’t preclude living kidney donation, but candidates should be counseled on gestational hypertension risk.

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant

Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant

Todays Updates

Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status Marco Meglio

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

NeurologyLive® Friday 5 — October 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

Is Pregnancy Riskier for Living Kidney Donors? With Amit X. Garg, MD, PhD Amit X. Garg, MD, PhD

A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.

Counseling Kidney Donors on Future Pregnancy, With Amit Garg, MD, PhD Amit X. Garg, MD, PhD

Future pregnancy plans don’t preclude living kidney donation, but candidates should be counseled on gestational hypertension risk.

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant

Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant

Latest News

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
HTTP error: 503

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

News All Time

HTTP error: 503

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!

First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy Marco Meglio

A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome Matt Hoffman

All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli

New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio

The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Recommended News For You

Why breast cancer survivors don't take their medicine, and what can be done about it.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

A new theranostic drug targets different cancer types.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

Are ultramarathon runners really at increased risk of bowel cancer?

Recommended Articles For You

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment 

Integrated Insights in Hematology and Quality Improvement 

Tumor Ecosystem Profiles for Therapy Matching 

Understanding Acute Myeloid Leukemia (AML) and Its Survival Rates 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

2.

healthy despite having advanced cancer.

3.

TKI Discontinuation Feasible After ALL Treatment

4.

De-escalation Misses the Mark in Inflammatory Breast Cancer

5.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

1.

Treating Methemoglobinemia: What You Need to Know Now!

2.

Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions

3.

Virtual Survivorship Platforms in Cancer Care: Transforming Post-Treatment Support and Outcomes

4.

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life

5.

Cancer Prehabilitation and Functional Recovery Pathways: An Evidence-Based Review

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

2.

Signs and Symptoms of Leukemia

3.

Efficient Management of First line ALK-rearranged NSCLC - Part III

4.

Navigating the Complexities of Ph Negative ALL - Part V

5.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot